EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024–2025 Italian Universal Immunization Campaign in Newborns

Cinzia Auriti iD, Camilla Gizzi iD, Matteo Riccò iD, Roberto Bellù, Mario Giuffrè iD, Adele Fabiano iD, Caterina Cacace iD, Paola Cavicchioli, Armando Cuttano iD, Susanna Di Valerio, Cristiana Germini, Marcello Napolitano iD und 10 weitere

Viruses · 2026

DOI: 10.3390/v18090982 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Viruses, 2026. Verfasst von Cinzia Auriti und 21 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, General and Specialist Pediatrics, Saint Camillus International University of Health and Medical Sciences (Unicamillus), 00131 R…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antiviral Agents, Bronchiolitis, Respiratory Syncytial Virus Infections. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Society of Neonatology will have in charge publication fees, Italian Society of Neonatology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infection (LRTI) and hospitalization in early infancy. Following the introduction of universal nirsevimab prophylaxis in Italy during the 2024–2025 RSV season, we evaluated its real-world effectiveness against RSV-associated hospitalization and severe clinical outcomes within a test-negative design framework. We conducted a multicenter retrospective test-negative study across 88 Italian neonatal centers, including infants hospitalized for LRTI from 1 September 2024 to 30 April 2025. Clinical data were collected from hospital records using a standardized electronic questionnaire. RSV-positive hospitalized infants were considered cases, and RSV-negative hospitalized infants served as controls. Secondary outcomes included respiratory support and Neonatal Intensive Care Unit (NICU) admission. Effectiveness was estimated using multivariable logistic regression and targeted maximum likelihood estimation. Overall, 737 infants were included, of whom 306 (41.52%) had previously received nirsevimab. RSV infection was identified in 398 infants (54.00%), including 104/306 (33.99%) nirsevimab-immunized and 294/431 (68.21%) non-immunized infants (p < 0.001). Immunized infants also required respiratory support less frequently (55.23% vs. 70.07%; p < 0.001), with lower use of high-flow oxygen therapy (40.85% vs. 48.96%; p = 0.036) and Continuous Positive Airway Pressure (CPAP) (18.95% vs. 33.87%; p < 0.001). Within the test-negative design framework, adjusted effectiveness against RSV-associated hospitalization was estimated at 78.3%. Among hospitalized infants, previous nirsevimab immunization was additionally associated with adjusted relative reductions in the odds of respiratory support and NICU admission of 80.2% and 64.3%, respectively. In conclusion, among infants hospitalized for LRTI in routine Italian clinical practice, previous nirsevimab immunization was associated with lower odds of RSV positivity and a reduced need for respiratory support. Although these findings provide further evidence of the real-world effectiveness of nirsevimab against severe RSV disease, further studies are needed to provide direct estimates of hospitalization incidence in immunized and non-immunized source populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntiviral AgentsBronchiolitisRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsFemaleHumansInfantInfant, NewbornMaleHospitalizationImmunization ProgramsItalyRespiratory Syncytial Virus, HumanRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

RSVbronchiolitishospitalizationinfantlower respiratory tract infectionnewbornnirsevimabprophylaxisrespiratory support

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral Agents

Autor:innen und Institutionen

  • Faculty of Medicine, General and Specialist Pediatrics, Saint Camillus International University of Health and Medical Sciences (Unicamillus), 00131 Rome, Italy.
  • Neonatal Intensive Care Unit S., Eugenio Hospital, 00144 Rome, Italy.
  • Servizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), AUSL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
  • Neonatal Intensive Care and Neonatal Units, Lecco Hospital of Lecco ASST, 23900 Lecco, Italy.
  • Neonatal Intensive Care Unit and Pediatrics, G. D'Alessandro Department, Palermo University, 90127 Palermo, Italy.
  • Neonatal Intensive Care Unit, San Giovanni Hospital, 00184 Rome, Italy.

ORCID-Profile: Cinzia Auriti, Camilla Gizzi, Matteo Riccò, Mario Giuffrè, Adele Fabiano, Caterina Cacace, Armando Cuttano, Marcello Napolitano, Chiara Peila, Serafina Perrone, Massimo Agosti

Förderung

  • Italian Society of Neonatology will have in charge publication fees
  • Italian Society of Neonatology

Zitieren

APA

Auriti, C., Gizzi, C., Riccò, M., Bellù, R., Giuffrè, M., Fabiano, A., Cacace, C., Cavicchioli, P., Cuttano, A., Valerio, S. D., Germini, C., Napolitano, M., Paviotti, G., Peila, C., Perrone, S., Pesce, S., Scarpelli, G., Scutti, G., Spanedda, G., …, & On Behalf Of The Italian Working Group On Rsv Prophylaxis Of Italian Society Of Neonatology (2026). Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024–2025 Italian Universal Immunization Campaign in Newborns. Viruses. https://doi.org/10.3390/v18090982

Vancouver

Auriti C, Gizzi C, Riccò M, Bellù R, Giuffrè M, Fabiano A, et al. Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024–2025 Italian Universal Immunization Campaign in Newborns. Viruses. 2026. doi:10.3390/v18090982

BibTeX
@article{Auriti2026,
  author = {Auriti, Cinzia and Gizzi, Camilla and Riccò, Matteo and Bellù, Roberto and Giuffrè, Mario and Fabiano, Adele and Cacace, Caterina and Cavicchioli, Paola and Cuttano, Armando and Valerio, Susanna Di and Germini, Cristiana and Napolitano, Marcello and Paviotti, Giulia and Peila, Chiara and Perrone, Serafina and Pesce, Simona and Scarpelli, Gianfranco and Scutti, Grazia and Spanedda, Giuseppina and Staffler, Alex and Agosti, Massimo and On Behalf Of The Italian Working Group On Rsv Prophylaxis Of Italian Society Of Neonatology},
  title = {Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024–2025 Italian Universal Immunization Campaign in Newborns},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18090982}
}
Kostenlos starten →